Applied dna ships first sarna (self-amplifying mrna) ivt template generated by linea(tm) dna platform

- preclinical orders for additional customers underway - stony brook, ny / accesswire / november 9, 2023 / applied dna sciences, inc. (nasdaq:apdn) ("applied dna" or the "company"), a leader in pcr-based dna technologies, today announced that it has successfully manufactured and shipped its first research use only quantity of self-amplifying mrna (sarna) template generated by its linea™ dna platform (the "platform") to an unidentified preclinical therapeutic mrna developer. sarna is a promising new form of mrna therapy engineered to possess a self-replicating capability.
APDN Ratings Summary
APDN Quant Ranking